Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles
Key facts
- Where
- Kolding és Odense, DániaSee the 4 sites
Where in Dánia
- Kolding HospitalKolding, DániaToborzás még nem indult
- Department of NephrologyOdense, DániaToborzás még nem indult
- Department of RheumatologyOdense, DániaTaking people
- Univesity of Southern DenmarkOdense, DániaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kolding Sygehus
- Trial code
- NCT06642402
- Record updated
- 2025. szeptember 9.
- Original description
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.Read full original descriptionShow less
Monitoring and Detecting Lupus Nephritis Through Urinary Extracellular Vesicles in Urine
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.
Inclusion: > 18 years old; Fulfilling the 2019 EULAR/ACR classification criteria; Positive autoantibodies, medical history and obejctive examination compatible with SLE; Referred to kidney biopsy; > 18 years old; Fulfilling the 2019 EULAR/ACR classification criteria; Positive autoantibodies, medical history and obejctive examination compatible with SLE; Normal plasma creatinine; Urine albumine/creatinine < 100 mg/g; > 18 years old; No known kidney disease; > 18 years old; Negative autoantibiodies and immunoglobulines; Referred to kidney biopsy.
Exclusion: Significant comorbidity, which is considered to potentially impact the outcome; SLE patients with no sign of kidney disease; Urine albumin-creatinine ratio > 100 mg/g or proteinuria > 100 mg/day; Lack of ability or willingness to provide informed consent; Lack of ability or willingness to provide informed consent; Significant comorbidity, which is considered to potentially impact the outcome; Healthy controls:; Lack of ability or willingness to provide informed consent; Postive autoantibodies; Significant comorbidity, which is considered to potentially impact the outcome; Biopsy control:; Lack of ability or willingness to provide informed consent; Significant comorbidity, which is considered to potentially impact the outcome.
SLE patients with kidney involvement.